Transcode TherapeuticsRNAZ
13F holders, Q2 2025 (June 30)9holders
$7.80avg. 13F price*
At the end of Q2 2025, 9 institutions reported holding Transcode Therapeutics Inc. (RNAZ) in their 13F filings. The largest holders were Goldman Sachs Group Inc. ($219K), UBS Group AG ($11K) and SouthState Bank Corp ($4K).
- Company
- Transcode Therapeutics Inc.
- CUSIP
- 89357L501
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q2 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $219K |
| Exits | 0 | $0 |
Ownership 9 holders
| Goldman Sachs Group Inc. | 0.00% | New | 28,042 | $219K |
| UBS Group AG | 0.00% | Reduce -82.5% | 1,432 | $11K |
| SouthState Bank Corp | 0.00% | Reduce -13.7% | 482 | $4K |
| Tower Research Capital LLC (TRC) | 0.00% | Add +749.2% | 402 | $3K |
| SBI Securities Co., Ltd. | 0.00% | Reduce -13.8% | 10 | $78 |
| Bank of America Corp. | 0.00% | Add +4201.1% | 8 | $63 |
| FMR LLC | 0.00% | Add +287.1% | 3 | $23 |
| Osaic Holdings, Inc. | 0.00% | Reduce -3.2% | 3 | $23 |
| Royal Bank of Canada | 0.00% | Add +3.2% | 8 | $0 |
"% of holder's portfolio" is RNAZ's weight in each manager's 13F, not the share of Transcode Therapeutics Inc. the manager owns.